Analyst Price Targets — LLY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 9:06 pm | Trung Huynh | RBC Capital | $1,250.00 | $1,042.15 | StreetInsider | RBC Capital Starts Eli Lilly (LLY) at Outperform |
| February 19, 2026 9:12 pm | — | Barclays | $1,350.00 | $1,023.22 | TheFly | Eli Lilly initiated with an Overweight at Barclays |
| February 10, 2026 8:24 pm | Ilya Zubkov | Loop Capital Markets | $1,200.00 | $1,025.00 | StreetInsider | Freedom Capital Markets Upgrades Eli Lilly (LLY) to Buy |
| February 5, 2026 3:43 pm | — | Scotiabank | $1,300.00 | $1,037.13 | TheFly | Eli Lilly price target raised to $1,300 from $1,165 at Scotiabank |
| February 5, 2026 3:05 pm | — | Truist Financial | $1,281.00 | $1,027.51 | TheFly | Eli Lilly price target raised to $1,281 from $1,182 at Truist |
| February 5, 2026 12:50 pm | — | Goldman Sachs | $1,260.00 | $1,107.12 | TheFly | Eli Lilly price target raised to $1,260 from $1,145 at Goldman Sachs |
| February 5, 2026 12:43 pm | Mohit Bansal | Wells Fargo | $1,280.00 | $1,107.12 | TheFly | Eli Lilly price target raised to $1,280 from $1,200 at Wells Fargo |
| February 5, 2026 12:26 pm | Evan Seigerman | BMO Capital | $1,300.00 | $1,107.12 | TheFly | Eli Lilly price target raised to $1,300 from $1,200 at BMO Capital |
| January 20, 2026 12:21 pm | — | Guggenheim | $1,161.00 | $1,038.40 | TheFly | Eli Lilly price target lowered to $1,161 from $1,163 at Guggenheim |
| January 6, 2026 10:03 pm | Michael Yee | UBS | $1,250.00 | $1,064.04 | TheFly | Eli Lilly assumed with a Buy at UBS |
Latest News for LLY
Eli Lilly CFO Lucas Montarce said on Monday it is preparing to launch its new oral obesity drug, orforglipron, in the United States as early as the second quarter of this year, once it gets approval from the Food and Drug Administration.
Eli Lilly's ongoing innovations could set the business up for a long time. The company also has a strong dividend program.
Eli Lilly wins CHMP backing to expand Olumiant use in adolescents with severe alopecia areata, with the EU approval decision expected shortly.
Novo Nordisk is investing $506 million to expand manufacturing capabilities in Ireland. The move will strengthen its ability to meet both current and future demand for its oral medicines, said Novo executive Kasper Bødker Mejlvang.
Eli Lilly (NYSE: LLY) stock has pulled back 2.9% year-to-date to around $1,044, and institutional investors have been accumulating shares during the pullback, according to recent filings.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.